Protagonist Therapeutics Inc (PTGX)

$35.71

-0.21

(-0.58%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $35.09
    $36.43
    $35.71
    downward going graph

    1.74%

    Downside

    Day's Volatility :3.68%

    Upside

    1.98%

    downward going graph
  • $13.72
    $38.03
    $35.71
    downward going graph

    61.58%

    Downside

    52 Weeks Volatility :63.92%

    Upside

    6.1%

    downward going graph

Returns

PeriodProtagonist Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
39.44%
5.9%
0.0%
6 Months
44.17%
5.5%
0.0%
1 Year
79.09%
10.9%
0.0%
3 Years
-23.57%
15.6%
-17.0%

Highlights

Market Capitalization
2.1B
Book Value
$9.56
Earnings Per Share (EPS)
2.54
PE Ratio
14.06
PEG Ratio
0.0
Wall Street Target Price
44.8
Profit Margin
51.47%
Operating Margin TTM
80.92%
Return On Assets TTM
21.38%
Return On Equity TTM
41.75%
Revenue TTM
315.0M
Revenue Per Share TTM
5.31
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
26.6M
EBITDA
149.6M
Diluted Eps TTM
2.54
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
1.39
EPS Estimate Next Year
-1.6
EPS Estimate Current Quarter
1.19
EPS Estimate Next Quarter
0.34

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Protagonist Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 25.46%

Current $35.71
Target $44.80

Technicals Summary

Sell

Neutral

Buy

Protagonist Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc
13.62%
44.17%
79.09%
-23.57%
171.77%
Moderna, Inc.
Moderna, Inc.
-9.73%
21.69%
-3.08%
-61.31%
759.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
2.19%
14.34%
48.43%
82.37%
258.01%
Novo Nordisk A/s
Novo Nordisk A/s
-7.8%
21.53%
62.25%
194.33%
441.74%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.55%
12.21%
36.13%
144.99%
180.32%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc
14.06
14.06
0.0
1.39
0.42
0.21
NA
9.56
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.06
32.06
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.67
31.67
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc
Buy
$2.1B
171.77%
14.06
51.47%
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
759.82%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$119.6B
258.01%
32.06
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
441.74%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
180.32%
31.67
39.46%

Insights on Protagonist Therapeutics Inc

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 194.3% return, outperforming this stock by 217.9%

Institutional Holdings

  • Farallon Capital Management, L.L.C.

    9.78%
  • BlackRock Inc

    9.50%
  • RTW INVESTMENTS, LLC

    9.06%
  • Bvf Inc

    6.40%
  • State Street Corporation

    5.58%
  • Vanguard Group Inc

    5.44%

Company Information

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist

Organization
Protagonist Therapeutics Inc
Employees
124
CEO
Dr. Dinesh V. Patel Ph.D.
Industry
Health Technology

FAQs